Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Adaptimmune Therapeutics Plc (ADAP) AI Forecast

Our AI analyzed Adaptimmune Therapeutics Plc. Create a free account to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$ADAP Neutral Signal Full forecast available
Sign Up Free

Adaptimmune Therapeutics Plc (ADAP) Stock Forecast 2025

Adaptimmune Therapeutics Plc (ADAP) AI Stock Price Forecast & Investment Analysis

Adaptimmune Therapeutics Plc Stock Price Chart and Technical Analysis

Loading chart...

Adaptimmune Therapeutics Plc (ADAP) - Comprehensive Stock Analysis & Investment Research

Deep dive into Adaptimmune Therapeutics Plc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on March 3, 2026, 5:32 p.m. (UTC)

Adaptimmune Therapeutics Plc Investment Summary

When evaluating whether Adaptimmune Therapeutics Plc (ADAP) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Adaptimmune Therapeutics Plc (ADAP) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $77 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Adaptimmune Therapeutics Plc's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Adaptimmune Therapeutics Plc along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Adaptimmune Therapeutics Plc is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Adaptimmune Therapeutics Plc

Sign Up Free
Corporate Identity

Adaptimmune Therapeutics Plc (Stock Symbol: ADAP) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Adaptimmune Therapeutics Plc's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Adaptimmune Therapeutics Plc...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Adaptimmune Therapeutics Plc...

Unlock Full Company Profile

Get complete details about Adaptimmune Therapeutics Plc

Sign Up Free
Revenue & Growth Analysis

Adaptimmune Therapeutics Plc generates annual revenues of $65 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Adaptimmune Therapeutics Plc...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Adaptimmune Therapeutics Plc...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Adaptimmune Therapeutics Plc...

Unlock Financial Analysis

Get complete financial metrics for Adaptimmune Therapeutics Plc

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Adaptimmune Therapeutics Plc's AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Adaptimmune Therapeutics Plc strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Adaptimmune Therapeutics Plc competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency
Margin & Pricing Power Analysis

The company maintains a 1.9% gross margin characteristic of commodity-like businesses or high-volume, low-margin operators. Thin gross margins require exceptional operational efficiency and volume to generate meaningful profits. Companies at this margin level are particularly sensitive to cost increases or pricing pressures.

Operating margin of -576.6% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. Operating margin compression relative to gross margin suggests high operating expenses that may warrant efficiency improvements or reflect necessary growth investments.

Financial Strength & Leverage

Adaptimmune Therapeutics Plc (ADAP) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Adaptimmune Therapeutics Plc stock analysis.

Deep dive into Adaptimmune Therapeutics Plc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Adaptimmune Therapeutics Plc stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Adaptimmune Therapeutics Plc: With a P/E ratio of -13.20, the market sees the stock as potentially undervalued.

P/E Ratio -13.20x
P/B Ratio -11.77x
Market Cap $77M
EPS $-0.11
Book Value/Share $-0.02
Revenue/Share $0.04
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Adaptimmune Therapeutics Plc converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Adaptimmune Therapeutics Plc:

Gross Margin 1.9%
Operating Margin -576.6%
Net Margin -533.8%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Adaptimmune Therapeutics Plc's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Adaptimmune Therapeutics Plc:

Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Adaptimmune Therapeutics Plc's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Adaptimmune Therapeutics Plc:

Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Adaptimmune Therapeutics Plc uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Adaptimmune Therapeutics Plc:

Understanding Financial Statement Data

What these metrics mean: Key figures from Adaptimmune Therapeutics Plc's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Adaptimmune Therapeutics Plc: With annual revenue of $65M, Adaptimmune Therapeutics Plc represents a smaller but potentially high-growth operation.

Income Statement
Total Revenue $65M
Operating Income -$67M
Net Income -$62M
R&D Expense $56M
Balance Sheet Highlights (% Of Assets)
Dividend & Shareholder Information
Shares Outstanding 1590M
Growth Metrics (YoY)
EPS Growth -7.1%

Latest Adaptimmune Therapeutics Plc Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Adaptimmune Therapeutics Plc (ADAP) stock price and investment outlook.

More news available

Sign up free to read all 9 news articles and stay updated on market developments.

Sign Up Free to Read More

Adaptimmune Therapeutics Plc Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Adaptimmune Therapeutics Plc against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Acumen Pharmaceuticals, Inc. ABOS ██% $200M -1.9x 2.2x
Abpro Holdings, Inc. ABP ██% $1M x 0.0x
Arcellx, Inc. ACLX ██% $6.61B -74.1x 16.4x
Alpha Cognition Inc. ACOG ██% $126M x 3.7x
Adaptimmune Therapeutics Plc ADAP ██% $77M -13.2x -11.8x
Adma Biologics, Inc. ADMA ██% $3.94B 26.8x 8.3x
Adaptive Biotechnologies Corp ADPT ██% $2.48B -4.6x 11.3x
Adverum Biotechnologies, Inc. ADVM ██% $95M -1.8x 2.2x
Agenus Inc AGEN ██% $110M -0.5x 32.1x
Agentix Corp. AGTX ██% $2M x 296.8x
Aim Immunotech Inc. AIM ██% $3M -0.5x 0.9x
Aim Immunotech Inc. AIMI ██% $1M x x
Alector, Inc. ALEC ██% $244M -1.2x 8.0x
Aligos Therapeutics, Inc. ALGS ██% $43M -19.2x 0.6x
Allogene Therapeutics, Inc. ALLO ██% $591M -1.4x 1.9x
Alvotech ALVO ██% $1.20B x x
Amgen Inc AMGN ██% $207.82B 27.0x 24.0x
Apogee Therapeutics, Inc. APGE ██% $4.84B -20.5x 4.3x
Aptose Biosciences Inc. APTOF ██% $4M x x
Argenx Se ARGX ██% $45.98B x x
Armata Pharmaceuticals, Inc. ARMP ██% $416M -1.0x 21.7x
Artiva Biotherapeutics, Inc. ARTV ██% $123M x 1.0x
Leonabio, Inc. ATHA ██% $23M -0.2x 0.9x
Atara Biotherapeutics, Inc. ATRA ██% $35M 1.5x 4.8x
Atyr Pharma Inc ATYR ██% $97M -3.6x 1.2x
Aura Biosciences, Inc. AURA ██% $387M -4.9x 2.5x
Autolus Therapeutics Plc AUTL ██% $444M x 1.7x
Anavex Life Sciences Corp. AVXL ██% $408M -17.3x 3.2x
Bioatla, Inc. BCAB ██% $15M -1.1x 27.7x
Biocardia, Inc. BCDA ██% $14M -0.6x 5.5x
Brainstorm Cell Therapeutics Inc. BCLI ██% $8M -4.9x 5.6x
Biocryst Pharmaceuticals Inc BCRX ██% $1.87B -12.1x 55.7x
Black Diamond Therapeutics, Inc. BDTX ██% $147M 6.9x 1.2x
Beam Therapeutics Inc. BEAM ██% $3.01B -12.6x 2.4x
Biogen Inc. BIIB ██% $27.61B 21.4x 1.9x
Biontech Se BNTX ██% $26.97B x x
Cabaletta Bio, Inc. CABA ██% $317M -1.6x 2.3x
Candel Therapeutics, Inc. CADL ██% $281M -4.6x 3.5x
C4 Therapeutics, Inc. CCCC ██% $232M -2.6x 1.5x
Cidara Therapeutics, Inc. CDTX ██% $6.49B -1.0x 15.4x
Creative Medical Technology Holdings, Inc. CELZ ██% $6M -3.4x 1.1x
Cero Therapeutics Holdings, Inc. CERO ██% $800K x -196.2x
Cullinan Therapeutics, Inc. CGEM ██% $945M -4.1x 2.1x
Compugen Ltd CGEN ██% $213M x 2.1x
Cg Oncology, Inc. CGON ██% $4.66B x 6.2x
Cognition Therapeutics Inc CGTX ██% $94M -0.5x 2.6x
Coherus Oncology, Inc. CHRS ██% $247M 1.6x 2.8x
Calidi Biotherapeutics, Inc. CLDI ██% $6M -0.9x 0.8x
Cellectis S.A. CLLS ██% $400M x x
Compass Therapeutics, Inc. CMPX ██% $1.01B -4.8x 4.8x
Mosaic Immunoengineering Inc. CPMV ██% $5M x 19.8x
Caribou Biosciences, Inc. CRBU ██% $142M -1.5x 1.0x
Cardiff Oncology, Inc. CRDF ██% $133M -4.0x 2.9x
Cardiol Therapeutics Inc. CRDL ██% $114M x x
Curis Inc CRIS ██% $14M -0.3x 1.5x
Crispr Therapeutics Ag CRSP ██% $5.83B -12.1x 3.0x
Champions Oncology, Inc. CSBR ██% $84M 33.8x 20.2x
Cel Sci Corp CVM ██% $32M -0.9x 2.9x
Dbv Technologies S.A. DBVT ██% $1.28B -3.3x 24.2x
Dbv Technologies S.A. DBVTF ██% $10K x 0.0x
Ginkgo Bioworks Holdings, Inc. DNA ██% $410M -13.9x 0.8x
Denali Therapeutics Inc. DNLI ██% $3.28B -8.7x 3.2x
Precision Biosciences Inc DTIL ██% $104M -2.2x 6.3x
Dyadic International Inc DYAI ██% $28M -7.3x 10.7x
Editas Medicine, Inc. EDIT ██% $201M -0.8x 14.9x
Elutia Inc. ELUT ██% $47M -1.4x 7.1x
Engene Holdings Inc. ENGN ██% $670M 3.7x 4.0x
Entera Bio Ltd. ENTX ██% $63M 8.5x 4.2x
Enzon Pharmaceuticals, Inc. ENZN ██% $4M x 10.3x
Estrella Immunopharma, Inc. ESLA ██% $48M -3.1x 333.4x
Evaxion A/S EVAX ██% $26M x x
Exelixis, Inc. EXEL ██% $10.77B 13.8x 5.0x
Exozymes Inc. EXOZ ██% $68M x 12.6x
Fate Therapeutics Inc FATE ██% $171M -1.3x 0.8x
4d Molecular Therapeutics, Inc. FDMT ██% $533M -3.0x 1.5x
Fennec Pharmaceuticals Inc. FENC ██% $290M 1758.3x 96.2x
Finch Therapeutics Group, Inc. FNCH ██% $21M -0.1x 1.5x
Futuretech Ii Acquisition Corp. FTII ██% $52M x -0.7x
Futuretech Ii Acquisition Corp. FTIIU ██% $14M x -0.8x
Gilead Sciences, Inc. GILD ██% $186.19B 21.9x 8.2x
Monte Rosa Therapeutics, Inc. GLUE ██% $1.35B 64.6x 5.5x
Genenta Science S.P.A. GNTA ██% $23M x 1.8x
Green Planet Bio Engineering Co. Ltd. GPLB ██% $340K x x
Halozyme Therapeutics, Inc. HALO ██% $8.23B 26.0x 168.5x
Humacyte, Inc. HUMA ██% $215M -3.3x 53.1x
Immunitybio, Inc. IBRX ██% $10.56B -3.6x 90.0x
Inhibikase Therapeutics, Inc. IKT ██% $234M -1.0x 3.2x
Immunocore Holdings Plc IMCR ██% $1.66B x 4.4x
Immatics N.V. IMTX ██% $1.21B x x
Immunovant, Inc. IMVT ██% $5.64B -14.5x 5.7x
In8bio, Inc. INAB ██% $17M x 1.3x
Inhibrx Biosciences, Inc. INBX ██% $1.12B -6.8x 30.5x
Mink Therapeutics, Inc. INKT ██% $51M -1.5x 7.6x
Inmune Bio, Inc. INMB ██% $35M -2.5x 1.4x
Intensity Therapeutics, Inc. INTS ██% $19M -2.2x 2.7x
Iovance Biotherapeutics, Inc. IOVA ██% $1.56B -4.5x 2.2x
Century Therapeutics, Inc. IPSC ██% $196M -0.7x 1.1x
Invivyd, Inc. IVVD ██% $485M -0.4x 5.2x
Jasper Therapeutics, Inc. JSPR ██% $38M -3.2x 3.3x
Kalaris Therapeutics, Inc. KLRS ██% $196M x 4.7x
Klotho Neurosciences, Inc. KLTO ██% $47M x 4.7x
Kodiak Sciences Inc. KOD ██% $1.64B -2.5x 69.1x
Krystal Biotech, Inc. KRYS ██% $7.56B 36.9x 6.2x
Kymera Therapeutics, Inc. KYMR ██% $7.33B -17.8x 4.6x
Kyverna Therapeutics, Inc. KYTX ██% $507M x 3.3x
Ladrx Corp LADX ██% $50K x 0.2x
Lineage Cell Therapeutics, Inc. LCTX ██% $449M -4.7x 20.4x
Lenz Therapeutics, Inc. LENZ ██% $391M -6.7x 2.0x
Liminatus Pharma, Inc. LIMN ██% $10M x x
Lexeo Therapeutics, Inc. LXEO ██% $524M -0.4x 4.3x
Maze Therapeutics, Inc. MAZE ██% $2.19B x 5.8x
Mesoblast Ltd MESO ██% $1.93B x x
Meiragtx Holdings Plc MGTX ██% $608M -3.4x 205.6x
Metagenomi, Inc. MGX ██% $57M x 0.3x
Molecular Partners Ag MOLN ██% $203M x x
Moderna, Inc. MRNA ██% $20.82B -3.2x 2.4x
Neurocrine Biosciences Inc NBIX ██% $13.25B 27.7x 4.1x
Nkgen Biotech, Inc. NKGN ██% $2M -0.1x -0.2x
Neumora Therapeutics, Inc. NMRA ██% $564M -3.9x 4.3x
Novavax Inc NVAX ██% $1.64B 3.7x 43.7x
Ocugen, Inc. OCGN ██% $606M -4.3x 171.5x
Outlook Therapeutics, Inc. OTLK ██% $31M -0.2x 3.0x
Palisade Bio, Inc. PALI ██% $263M -0.2x 81.8x
Passage Bio, Inc. PASG ██% $28M -0.6x 1.5x
Vaxcyte, Inc. PCVX ██% $8.12B -20.4x 3.0x
Biomx Inc. PHGE ██% $7M 1.5x 0.7x
Pluri Inc. PLUR ██% $35M -1.4x 363.8x
Protalix Biotherapeutics, Inc. PLX ██% $225M 41.8x 4.3x
Pharmacyte Biotech, Inc. PMCB ██% $7M 0.3x 0.2x
Prime Medicine, Inc. PRME ██% $791M -1.5x 6.5x
Prokidney Corp. PROK ██% $674M x 0.0x
Qiagen N.V. QGEN ██% $10.57B x 3.0x
Quince Therapeutics, Inc. QNCX ██% $5M -1.7x 4.6x
Qrons Inc. QRON ██% $150K x x
Replimune Group, Inc. REPL ██% $553M -3.8x 2.6x
Repligen Corp RGEN ██% $6.69B 136.9x 3.2x
Regenxbio Inc. RGNX ██% $446M -1.8x 2.8x
Relay Therapeutics, Inc. RLAY ██% $1.70B -2.0x 3.0x
Revolution Medicines, Inc. RVMD ██% $19.73B -11.1x 12.1x
Recursion Pharmaceuticals, Inc. RXRX ██% $1.87B -4.7x 1.7x
Sab Biotherapeutics, Inc. SABS ██% $181M 9.7x 1.1x
Sana Biotechnology, Inc. SANA ██% $1.02B -2.1x 5.2x
Scilex Holding Co SCLX ██% $58M -0.4x 5.5x
Scinai Immunotherapeutics Ltd. SCNI ██% $3M -287.8x 0.4x
Sangamo Therapeutics, Inc SGMO ██% $149M -1.6x 23.9x
Solid Biosciences Inc. SLDB ██% $466M -0.9x 2.1x
Silexion Therapeutics Corp SLXN ██% $5M x 0.7x
Senti Biosciences, Inc. SNTI ██% $25M -1.1x 3.1x
Scholar Rock Holding Corp SRRK ██% $4.39B -18.5x 17.9x
Surrozen, Inc./De SRZN ██% $238M -0.5x 5.1x
Sutro Biopharma, Inc. STRO ██% $335M -1.0x 7.5x
Protara Therapeutics, Inc. TARA ██% $341M -2.1x 2.6x
Tarsus Pharmaceuticals, Inc. TARS ██% $3.21B -12.4x 9.4x
Tc Biopharm (Holdings) Plc TCBPY ██% $130K x 0.1x
Tscan Therapeutics, Inc. TCRX ██% $62M -4.6x 0.4x
Bio-Techne Corp TECH ██% $9.20B 113.4x 4.6x
Tectonic Therapeutic, Inc. TECX ██% $439M -8.9x 1.8x
Instil Bio, Inc. TIL ██% $60M -1.1x 0.5x
Tenaya Therapeutics, Inc. TNYA ██% $122M -2.5x 1.5x
Tourmaline Bio, Inc. TRML ██% $1.23B -3.5x 4.8x
Taysha Gene Therapies, Inc. TSHA ██% $1.24B -3.0x 5.7x
Titan Pharmaceuticals Inc TTNP ██% $6M -0.5x 2.2x
Tevogen Bio Holdings Inc. TVGN ██% $52M x 3835.7x
Twist Bioscience Corp TWST ██% $2.97B -12.6x 6.5x
Voyager Acquisition Corp./Cayman Islands VACH ██% $338M 33.1x 0.0x
Voyager Acquisition Corp./Cayman Islands VACHU ██% $68M 6.7x 0.0x
Valneva Se VALN ██% $963M x x
Vericel Corp VCEL ██% $1.81B 109.3x 5.1x
Vir Biotechnology, Inc. VIR ██% $1.27B -2.0x 1.6x
Vivosim Labs, Inc. VIVS ██% $6M x 1.3x
Vor Biopharma Inc. VOR ██% $641M -0.6x 9.7x
Vaxart, Inc. VXRT ██% $169M -0.9x 6.3x
Voyager Therapeutics, Inc. VYGR ██% $227M 570.6x 1.0x
Windtree Therapeutics Inc /De/ WINT ██% $340K -0.4x 0.1x
X4 Pharmaceuticals, Inc XFOR ██% $284M 6.4x 4.6x
Zeo Scientifix, Inc. ZEOX ██% $19M x 27.6x
Zivo Bioscience, Inc. ZIVO ██% $36M -31.3x 23.6x
Zura Bio Ltd ZURA ██% $628M x 5.8x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Adaptimmune Therapeutics Plc Stock Forecast

How accurate are Adaptimmune Therapeutics Plc stock predictions?

Our AI model shows a 39% Spearman correlation coefficient for ADAP predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Adaptimmune Therapeutics Plc stock price forecasts?

Our analysis considers Adaptimmune Therapeutics Plc's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Adaptimmune Therapeutics Plc a good investment in 2025?

Based on our AI analysis, Adaptimmune Therapeutics Plc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Adaptimmune Therapeutics Plc forecasts updated?

Adaptimmune Therapeutics Plc stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

My Portfolio

Investment Dashboard

Loading your portfolio...